TYP — Tryptamine Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- AU$40.85m
- AU$38.02m
- AU$1.12m
Annual cashflow statement for Tryptamine Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 10 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.615 | 2.39 | 3.97 | 4.14 | 0.013 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.7 | -7.83 | -8.53 | -3.85 | -6 |
| Capital Expenditures | -0.632 | -1.63 | -1.13 | -0.285 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.318 | -0.174 | -0.11 | 0.008 | 1.68 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.95 | -1.8 | -1.24 | -0.277 | 1.68 |
| Financing Cash Flow Items | -0.022 | -0.898 | -0.065 | -0.359 | -0.619 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.97 | 20.6 | 1.88 | 0.919 | 9.27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.68 | 11 | -7.88 | -3.2 | 4.93 |